Pharmaceutical

Nusano to Participate in October Investor Conferences

NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced…

1 year ago

Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study

The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered…

1 year ago

NurExone Appoints Dr. Reuter Investor Relations in Europe

TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

1 year ago

Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical…

1 year ago

Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer

Gisele Deblandre, Cell-Easy's Chief Scientific Officer We're thrilled to welcome Gisele Deblandre as our new Chief Scientific Officer! TOULOUSE, France,…

1 year ago

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…

1 year ago

Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration

Companies Extend Collaboration After Successful Preclinical Study Assessed the Quris-AI BioAI Drug Safety PlatformBOSTON and TEL AVIV, Israel, Sept. 28,…

1 year ago

GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential…

1 year ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company…

1 year ago